Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Assets (2016 - 2025)

Rein Therapeutics filings provide 10 years of Current Assets readings, the most recent being $4.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 68.32% year-over-year to $4.3 million, compared with a TTM value of $4.3 million through Dec 2025, down 68.32%, and an annual FY2025 reading of $4.3 million, down 68.32% over the prior year.
  • Current Assets hit $4.3 million in Q4 2025 for Rein Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Current Assets was $64.3 million in Q1 2021, with the low at $4.3 million in Q4 2025.
  • Median Current Assets over the past 5 years was $18.5 million (2023), compared with a mean of $25.2 million.
  • The sharpest move saw Current Assets soared 369.96% in 2021, then crashed 72.31% in 2025.
  • Year by year, Current Assets stood at $48.2 million in 2021, then plummeted by 54.6% to $21.9 million in 2022, then dropped by 16.49% to $18.3 million in 2023, then fell by 25.23% to $13.7 million in 2024, then plummeted by 68.32% to $4.3 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $4.3 million, $5.2 million, and $6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.